APPENDIX 23 – DETAILED RESULTS OF GUIDELINE ECONOMIC ANALYSIS

Table 1. Base-case analysis, 5 years after treatment: NHS & PSS perspective. Mean total QALYs and costs per person with social anxiety presented along with 95% CIs; disaggregated costs provided

Intervention	Mean QALYs (95% CIs)		Mean total cost (£) (95% CIs)		Mean intervention cost (£)	Mean other NHS/ PSS cost (£)
Wait list	3.370	(3.250-3.633)	4,151	(2,791-5,827)	0	4,151
Placebo	3.400	(3.261-3.669)	4,241	(2,919-5,902)	137	4,104
Citalopram	3.448	(3.272-3.767)	4,175	(2,920-5,783)	149	4,026
Escitalopram	3.475	(3.283-3.792)	4,236	(2,997-5,815)	254	3,982
Fluoxetine	3.470	(3.281-3.787)	4,145	(2,918-5,750)	155	3,990
Fluvoxamine	3.490	(3.288-3.810)	4,178	(2,972-5,748)	222	3,956
Mirtazapine	3.470	(3.272-3.821)	4,141	(2,922-5,760)	152	3,989
Moclobemide	3.449	(3.274-3.754)	4,274	(3,020-5,873)	251	4,023
Paroxetine	3.507	(3.294-3.829)	4,097	(2,914-5,661)	169	3,928
Phenelzine	3.585	(3.323-3.893)	4,064	(2,966-5,502)	264	3,800
Pregabalin	3.450	(3.274-3.768)	4,428	(3,158-6,020)	406	4,022
Sertraline	3.442	(3.271-3.749)	4,193	(2,927-5,804)	157	4,036
Venlafaxine 75mg	3.515	(3.292-3.846)	4,169	(2,990-5,707)	253	3,916
Venlafaxine 150mg	3.497	(3.290-3.817)	4,257	(3,052-5,820)	312	3,945
Self-help (book) without support	3.532	(3.290-3.959)	4,064	(2,909-5,637)	181	3,883
Self-help (internet) without support	3.465	(3.273-3.865)	4,632	(3,368-6,279)	638	3,994
Self-help (book) with support	3.547	(3.291-3.995)	4,265	(3,089-5,866)	404	3,861
Self-help (internet) with support	3.548	(3.297-3.975)	4,715	(3,541-6,311)	858	3,857
Exposure	3.547	(3.294-3.979)	4,874	(3,732-6,434)	1,015	3,859
Psychodynamic psychotherapy	3.481	(3.276-3.897)	5,829	(3,976-7,561)	1,861	3,968
IPT	3.441	(3.265-3.830)	5,367	(3,819-7,109)	1,333	4,034
Supportive therapy	3.397	(3.253-3.736)	5,345	(3,813-7,125)	1,238	4,107
Mindfulness	3.439	(3.263-3.829)	4,522	(3,242-6,158)	485	4,037
CBT group	3.534	(3.293-3.956)	4,895	(3,742-6,470)	1,015	3,880
CBT individual	3.640	(3.323-4.085)	5,122	(3,621-6,699)	1,418	3,704
CBT Heimberg group	3.526	(3.289-3,943)	4,908	(3,753-6,495)	1,015	3,893
CBT Heimberg individual	3.616	(3.312-4.068)	5,209	(3,717-6,816)	1,465	3,744
CT (C&W) standard	3.752	(3.370-4.176)	5,539	(4,516-6,928)	2,019	3,520
CT (C&W) shortened	3.586	(3.306-4.028)	5,328	(3,716-6,958)	1,533	3,795

Table 2. Results of economic modelling one year after treatment - base-case analysis: NHS & PSS perspective

Intervention	Mean QALYs	Mean total costs (£)	Incremental analysis & ICERs (£/QALY)		Mean NMB per person (£)	Ranking in terms of highest NMB
	Per 1000 people					
CT (C&W) standard	944.09	2,755,253	51,057		16,127	14
CBT individual	912.41	2,202,652	ext dom		16,046	16
Phenelzine	910.75	1,052,960	2,162		17,162	1
CBT Heimberg individual	905.53	2,259,897	dominated		15,851	20
CT (C&W) shortened	896.87	2,340,708	dominated		15,597	26
Venlafaxine 75mg	887.45	1,077,190	dominated		16,672	3
Self-help (internet) with support	886.17	1,682,338	dominated		16,041	17
Exposure	885.92	1,839,820	dominated		15,879	19
Self-help (book) with support	885.85	1,228,928	dominated		16,488	6
Paroxetine	884.94	997,163	1,844		16,702	2
CBT group	882.19	1,845,385	dominated		15,798	21
Self-help (book) without support	881.55	1,012,294	dominated		16,619	4
Venlafaxine 150mg	881.53	1,145,453	dominated		16,485	7
CBT Heimberg group	879.96	1,848,809	dominated		15,750	24
Fluvoxamine	879.34	1,058,471	dominated		16,528	5
Escitalopram	874.28	1,097,576	dominated		16,388	10
Mirtazapine	872.75	998,442	dominated		16,457	8
Fluoxetine	872.49	1,001,970	dominated		16,448	9
Psychodynamic psychotherapy	867.11	2,714,038	dominated		14,628	29
Pregabalin	866.09	1,262,153	dominated		16,060	15
Moclobemide	865.78	1,106,954	dominated		16,209	13
Citalopram	865.17	1,006,748	dominated		16,297	11
Sertraline	863.20	1,017,126	dominated		16,247	12
Self-help (internet) without support	862.58	1,497,996	dominated		15,754	23
Interpersonal psychotherapy	855.75	2,203,513	dominated		14,911	27
Mindfulness	855.13	1,355,985	dominated		15,747	25
Placebo	849.45	1,017,803	dominated		15,971	18
Supportive therapy	843.11	2,127,352	dominated		14,735	28
Wait list	833.94	903,119			15,776	22

ext dom = dominated by extended dominance

Table 3. Base-case analysis, one year after treatment: NHS & PSS perspective. Mean total QALYs and costs per person with social anxiety presented along with 95% CIs; disaggregated costs provided

Intervention	Mean QALYs (95% CIs)		Mean total cost (£) (95% CIs)		Mean intervention cost (£)	Mean other NHS/ PSS cost (£)
Wait list	0.834	(0.804-0.903)	903	(599-1,281)	0	903
Placebo	0.849	(0.809-0.937)	1,018	(710-1,395)	137	881
Citalopram	0.865	(0.811-0.968)	1,006	(711-1,369)	149	857
Escitalopram	0.874	(0.815-0.975)	1,098	(755-1,452)	254	844
Fluoxetine	0.872	(0.814-0.974)	1,002	(706-1,357)	155	847
Fluvoxamine	0.879	(0.817-0.982)	1,058	(737-1,412)	222	836
Mirtazapine	0.873	(0.811-0.984)	998	(702-1,359)	152	846
Moclobemide	0.866	(0.812-0.964)	1,107	(766-1,469)	251	856
Paroxetine	0.885	(0.819-0.988)	997	(703-1,344)	169	828
Phenelzine	0.911	(0.828-1.008)	1,053	(723-1,374)	264	789
Pregabalin	0.866	(0.812-0.968)	1,262	(843-1,635)	406	856
Sertraline	0.863	(0.812-0.962)	1,017	(717-1,382)	157	860
Venlafaxine 75mg	0.887	(0.818-0.993)	1,077	(738-1,420)	253	824
Venlafaxine 150mg	0.882	(0.817-0.984)	1,145	(773-1,492)	312	833
Self-help (book) without support	0.882	(0.816-0.997)	1,012	(749-1,371)	181	831
Self-help (internet) without support	0.863	(0.810-0.972)	1,498	(1,146-1,917)	638	860
Self-help (book) with support	0.886	(0.817-1.006)	1,229	(896-1,628)	404	825
Self-help (internet) with support	0.886	(0.818-1,001)	1,682	(1,301-2,116)	858	824
Exposure	0.886	(0.818-1.001)	1,840	(1,591-2,188)	1,015	825
Psychodynamic psychotherapy	0.867	(0.812-0.979)	2,714	(1,185-3,255)	1,861	853
IPT	0.856	(0.809-0.961)	2,203	(1,090-2,718)	1,333	870
Supportive therapy	0.843	(0.806-0.936)	2,127	(1,105-2,650)	1,238	889
Mindfulness	0.855	(0.808-0.962)	1,356	(1,074-1,725)	485	871
CBT group	0.882	(0.817-0.995)	1,845	(1,594-2,197)	1,015	830
CBT individual	0.912	(0.825-1.029)	2,202	(1,036-2,686)	1,418	784
CBT Heimberg group	0.880	(0.816-0.992)	1,849	(1,596-2,204)	1,015	834
CBT Heimberg individual	0.906	(0.822-1.025)	2,260	(1,105-2,754)	1,465	795
CT (C&W) standard	0.944	(0.840-1.053)	2,755	(2,218-3,113)	2,019	736
CT (C&W) shortened	0.897	(0.821-1.014)	2,341	(1,080-2,863)	1,533	808

Figure 1. Cost-effectiveness plane of all interventions for adults with social anxiety assessed in the economic analysis plotted against wait list – incremental costs and QALYs per 1,000 adults with social anxiety, one year after treatment



Table 4. Results of secondary analysis: wider perspective including NHS & PSS costs as well as social security benefits, one year after treatment

Intervention	Mean QALYs	Mean total costs (£)	Incremental analysis & ICERs (£/QALY)		Mean NMB per person (£)	Ranking in terms of highest NMB
	Per 1000 people					
CT (C&W) standard	944.09	4,431,527	46,335		14,450	9
CBT individual	912.41	4,021,092	ext dom		14,227	13
Phenelzine	910.75	2,886,668			15,328	1
CBT Heimberg individual	905.53	4,109,436	dominated		14,001	18
CT (C&W) shortened	896.87	4,229,489	dominated		13,708	24
Venlafaxine 75mg	887.45	3,013,880	dominated		14,735	3
Self-help (internet) with support	886.17	3,619,611	dominated		14,104	16
Exposure	885.92	3,778,596	dominated		13,940	19
Self-help (book) with support	885.85	3,167,283	dominated		14,550	6
Paroxetine	884.94	2,945,206	dominated		14,754	2
CBT group	882.19	3,800,665	dominated		13,843	21
Self-help (book) without support	881.55	2,970,669	dominated		14,660	4
Venlafaxine 150mg	881.53	3,108,427	dominated		14,522	7
CBT Heimberg group	879.96	3,814,202	dominated		13,785	22
Fluvoxamine	879.34	3,031,447	dominated		14,555	5
Escitalopram	874.28	3,092,902	dominated		14,393	11
Mirtazapine	872.75	3,001,628	dominated		14,453	8
Fluoxetine	872.49	3,004,969	dominated		14,445	10
Psychodynamic psychotherapy	867.11	4,736,252	dominated		12,606	28
Pregabalin	866.09	3,293,811	dominated		14,028	17
Moclobemide	865.78	3,139,886	dominated		14,176	15
Citalopram	865.17	3,042,205	dominated		14,261	12
Sertraline	863.20	3,061,580	dominated		14,202	14
Self-help (internet) without support	862.58	3,541,464	dominated		13,710	23
IPT	855.75	4,277,447	dominated		12,838	27
Mindfulness	855.13	3,432,592	dominated		13,670	25
Placebo	849.45	3,122,972	dominated		13,866	20
Supportive therapy	843.11	4,257,978	dominated		12,604	29
Wait list	833.94	3,074,095	dominated		13,605	26

ext dom = dominated by extended dominance

Table 5. Results of secondary analysis: wider perspective including NHS & PSS costs as well as social security benefits, 5 years after treatment

Intervention	Mean QALYs	Mean total costs (£)	Incremental analysis & ICERs (£/QALY)		Mean NMB per person (£)	Ranking in terms of highest NMB
	Per 1000 people					
CT (C&W) standard	3,752	13,606,791	3,857		61,427	1
CBT individual	3,640	13,735,759	dominated		59,070	2
CBT Heimberg individual	3,616	13,942,287	dominated		58,379	4
CT (C&W) shortened	3,586	14,210,638	dominated		57,502	6
Phenelzine	3,585	12,964,689			58,739	3
Self-help (internet) with support	3,548	13,784,122	dominated		57,177	8
Exposure	3,547	13,948,579	dominated		56,996	9
Self-help (book) with support	3,547	13,337,497	dominated		57,602	5
CBT group	3,534	14,033,078	dominated		56,649	12
Self-help (book) without support	3,532	13,214,610	dominated		57,421	7
CBT Heimberg group	3,526	14,084,930	dominated		56,441	13
Venlafaxine 75mg	3,515	13,411,342	dominated		56,885	10
Paroxetine	3,507	13,377,586	dominated		56,767	11
Venlafaxine 150mg	3,497	13,587,211	dominated		56,351	14
Fluvoxamine	3,490	13,540,898	dominated		56,265	15
Psychodynamic psychotherapy	3,481	15,223,774	dominated		54,398	25
Escitalopram	3,475	13,671,899	dominated		55,828	16
Mirtazapine	3,470	13,603,846	dominated		55,804	17
Fluoxetine	3,470	13,607,835	dominated		55,784	18
Self-help (internet) without support	3,465	14,108,696	dominated		55,194	20
Pregabalin	3,450	13,984,843	dominated		55,021	23
Moclobemide	3,449	13,834,629	dominated		55,152	21
Citalopram	3,448	13,745,145	dominated		55,205	19
Sertraline	3,442	13,792,505	dominated		55,038	22
IPT	3,441	14,960,004	dominated		53,864	27
Mindfulness	3,439	14,125,236	dominated		54,655	24
Placebo	3,400	14,041,599	dominated		53,959	26
Supportive therapy	3,397	15,155,379	dominated		52,780	29
Wait list	3,370	14,091,476	dominated		53,307	28

ext dom = dominated by extended dominance

Table 6. Results of sensitivity analysis: use of alternative unit costs for self-help and group-delivered psychological interventions, one year after treatment

Intervention	Mean QALYs	Mean total costs (£)	Incremental analysis & ICERs (£/QALY)		Mean NMB per person (£)	Ranking in terms of highest NMB
	Per 1000 people					
CT (C&W) standard	943.70	2,753,108	51,474		16,121	15
CBT individual	912.26	2,201,852	ext dom		16,043	17
Phenelzine	910.69	1,054,025	2,446		17,160	1
CBT Heimberg individual	905.51	2,267,145	dominated		15,843	21
CT (C&W) shortened	896.78	2,354,823	dominated		15,581	26
Venlafaxine 75mg	887.47	1,077,889	dominated		16,671	3
Self-help (internet) with support	886.10	1,600,199	dominated		16,122	14
Exposure	885.81	1,783,229	dominated		15,933	19
Self-help (book) with support	885.76	1,147,906	dominated		16,567	5
Paroxetine	884.95	995,268	1,715		16,704	2
CBT group	882.16	1,788,635	dominated		15,855	20
Venlafaxine 150mg	881.54	1,143,293	dominated		16,488	7
Self-help (book) without support	881.53	982,690	dominated		16,648	4
CBT Heimberg group	879.94	1,792,100	dominated		15,807	22
Fluvoxamine	879.36	1,055,730	dominated		16,531	6
Escitalopram	874.35	1,095,995	dominated		16,391	10
Mirtazapine	872.74	997,218	dominated		16,458	8
Fluoxetine	872.52	1,001,292	dominated		16,449	9
Psychodynamic psychotherapy	867.14	2,716,179	dominated		14,627	29
Pregabalin	866.16	1,261,443	dominated		16,062	16
Moclobemide	865.91	1,103,520	dominated		16,215	13
Citalopram	865.24	1,003,822	dominated		16,301	11
Sertraline	863.26	1,015,303	dominated		16,250	12
Self-help (internet) without support	862.62	1,466,705	dominated		15,786	23
IPT	855.78	2,209,095	dominated		14,907	27
Mindfulness	855.31	1,329,002	dominated		15,777	25
Placebo	849.59	1,015,555	dominated		15,976	18
Supportive therapy	843.20	2,128,764	dominated		14,735	28
Wait list	834.07	901,313			15,780	24

ext dom = dominated by extended dominance

Table 7. Results of sensitivity analysis: use of alternative unit costs for self-help and group-delivered psychological interventions, 5 years after treatment

Intervention	Mean QALYs	Mean total costs (£)	Incremental analysis & ICERs (£/QALY)		Mean NMB per person (£)	Ranking in terms of highest NMB
	Per 1000 people					
CT (C&W) standard	3,750	5,530,445	8,944		69,464	1
CBT individual	3,639	5,114,810	ext dom		67,672	2
CBT Heimberg individual	3,616	5,209,711	dominated		67,103	4
Phenelzine	3,585	4,057,568	544		67,644	3
CT (C&W) shortened	3,585	5,335,318	dominated		66,363	7
Self-help (internet) with support	3,547	4,626,598	dominated		66,323	8
Exposure	3,546	4,811,421	dominated		66,117	10
Self-help (book) with support	3,546	4,176,272	dominated		66,748	5
CBT group	3,534	4,832,157	dominated		65,840	12
Self-help (book) without support	3,531	4,028,366			66,599	6
CBT Heimberg group	3,526	4,845,390	dominated		65,671	14
Venlafaxine 75mg	3,515	4,162,037	dominated		66,136	9
Paroxetine	3,507	4,088,864	dominated		66,057	11
Venlafaxine 150mg	3,497	4,248,297	dominated		65,692	13
Fluvoxamine	3,490	4,168,298	dominated		65,640	15
Psychodynamic psychotherapy	3,481	5,824,635	dominated		63,791	25
Escitalopram	3,475	4,226,101	dominated		65,280	16
Mirtazapine	3,470	4,132,933	dominated		65,276	17
Fluoxetine	3,470	4,137,717	dominated		65,258	18
Self-help (internet) without support	3,465	4,594,744	dominated		64,705	21
Pregabalin	3,451	4,420,531	dominated		64,590	23
Moclobemide	3,450	4,263,101	dominated		64,733	20
Citalopram	3,448	4,165,795	dominated		64,790	19
Sertraline	3,442	4,184,049	dominated		64,652	22
IPT	3,441	5,366,770	dominated		63,452	27
Mindfulness	3,439	4,488,838	dominated		64,297	24
Placebo	3,400	4,231,900	dominated		63,778	26
Supportive therapy	3,397	5,340,937	dominated		62,595	29
Wait list	3,370	4,142,708	dominated		63,265	28

ext dom = dominated by extended dominance

Table 8. Results of sensitivity analysis: use of alternative utility values, one year after treatment

Intervention	Mean QALYs	Mean total costs (£)	Incremental analysis & ICERs (£/QALY)		Mean NMB per person (£)	Ranking in terms of highest NMB
	Per 1000 people					
CT (C&W) standard	1,049.92	2,754,175	88,433		18,244	25
CBT individual	1,031.69	2,206,711	ext dom		18,427	22
Phenelzine	1,030.72	1,056,085	4,066		19,558	1
CBT Heimberg individual	1,027.75	2,265,208	dominated		18,290	24
CT (C&W) shortened	1,022.72	2,343,833	dominated		18,111	26
Venlafaxine 75mg	1,017.27	1,076,737	dominated		19,269	3
Self-help (internet) with support	1,016.57	1,681,988	dominated		18,649	17
Exposure	1,016.39	1,839,372	dominated		18,488	20
Self-help (book) with support	1,016.33	1,226,614	dominated		19,100	9
Paroxetine	1,015.83	995,544	3,170		19,321	2
CBT group	1,014.26	1,845,087	dominated		18,440	21
Venlafaxine 150mg	1,013.89	1,143,888	dominated		19,134	8
Self-help (book) without support	1,013.88	1,012,498	dominated		19,265	4
CBT Heimberg group	1,012.96	1,848,595	dominated		18,411	23
Fluvoxamine	1,012.60	1,058,503	dominated		19,194	5
Escitalopram	1,009.66	1,098,652	dominated		19,094	10
Mirtazapine	1,008.82	998,527	dominated		19,178	6
Fluoxetine	1,008.61	1,002,655	dominated		19,170	7
Psychodynamic psychotherapy	1,005.58	2,717,934	dominated		17,394	29
Pregabalin	1,004.93	1,263,015	dominated		18,836	15
Moclobemide	1,004.78	1,106,325	dominated		18,989	13
Citalopram	1,004.40	1,004,634	dominated		19,083	11
Sertraline	1,003.29	1,016,651	dominated		19,049	12
Self-help (internet) without support	1,002.94	1,498,178	dominated		18,561	19
IPT	998.98	2,207,193	dominated		17,772	27
Mindfulness	998.67	1,355,363	dominated		18,618	18
Placebo	995.36	1,017,442	dominated		18,890	14
Supportive therapy	991.68	2,121,863	dominated		17,712	28
Wait list	986.39	902,211			18,826	16

ext dom = dominated by extended dominance

Table 9. Results of sensitivity analysis: use of alternative utility values, 5 years after treatment

Intervention	Mean QALYs	Mean total costs (£)	Incremental analysis & ICERs (£/QALY)		Mean NMB per person (£)	Ranking in terms of highest NMB
	Per 1000 people					
CT (C&W) standard	4,178	5,538,318	15,328		78,013	1
CBT individual	4,113	5,126,559	ext dom		77,143	3
CBT Heimberg individual	4,100	5,214,576	dominated		76,777	6
CT (C&W) shortened	4,082	5,329,879	dominated		76,309	13
Phenelzine	4,082	4,066,518	83		77,564	2
Self-help (internet) with support	4,060	4,713,951	dominated		76,493	9
Exposure	4,060	4,871,667	dominated		76,322	12
Self-help (book) with support	4,059	4,260,270	dominated		76,930	5
CBT group	4,052	4,893,577	dominated		76,151	16
Self-help (book) without support	4,051	4,063,974			76,954	4
CBT Heimberg group	4,048	4,907,010	dominated		76,046	18
Venlafaxine 75mg	4,041	4,166,796	dominated		76,651	7
Paroxetine	4,037	4,094,563	dominated		76,637	8
Venlafaxine 150mg	4,031	4,254,306	dominated		76,360	10
Fluvoxamine	4,027	4,176,872	dominated		76,360	11
Psychodynamic psychotherapy	4,022	5,830,588	dominated		74,604	27
Escitalopram	4,018	4,234,044	dominated		76,125	17
Mirtazapine	4,015	4,139,201	dominated		76,169	14
Fluoxetine	4,015	4,144,253	dominated		76,151	15
Self-help (internet) without support	4,012	4,631,612	dominated		75,617	23
Pregabalin	4,004	4,426,774	dominated		75,646	22
Moclobemide	4,003	4,270,629	dominated		75,793	20
Citalopram	4,002	4,171,415	dominated		75,870	19
Sertraline	3,999	4,190,342	dominated		75,784	21
IPT	3,998	5,368,154	dominated		74,602	28
Mindfulness	3,997	4,519,156	dominated		75,428	24
Placebo	3,975	4,237,884	dominated		75,257	25
Supportive therapy	3,973	5,336,868	dominated		74,120	29
Wait list	3,957	4,147,311	dominated		74,999	26

ext dom = dominated by extended dominance